Protopic contains tacrolimus as its active component. It is a prescription-only topical ointment that belongs to the class of calcineurin inhibitors and is used to manage certain inflammatory skin conditions. In Hong Kong, Protopic is regulated by the Department of Health and is available in two strengths-0.03 % and 0.1 %-packaged in a tube form.
Tacrolimus, the active ingredient in Protopic, belongs to a group of drugs called calcineurin inhibitors. When applied to the skin, tacrolimus penetrates the outer layer and binds to an intracellular protein called FKBP-12. This complex blocks the activity of the enzyme calcineurin, which is essential for the activation of T-lymphocytes. By inhibiting T-cell activation, Protopic reduces the release of inflammatory cytokines such as interleukin-2, ultimately dampening the immune response that drives skin inflammation.
Key pharmacologic points:
Protopic is approved in Hong Kong for the topical treatment of:
The medication is intended for patients whose skin lesions are confined to limited areas; it is not indicated for widespread body coverage.
Research and clinical guidelines have explored additional applications of topical tacrolimus beyond its approved label:
These uses are not approved by the Hong Kong Department of Health. Off-label use requires individualized risk assessment by a qualified healthcare professional, and patients should be monitored for local irritation or systemic absorption.
Because systemic absorption is low, clinically significant drug-drug interactions are uncommon. However:
General Advice: Patients should inform their dermatologist of all prescription medications, over-the-counter products, supplements, and herbal preparations before starting Protopic.
Routine laboratory monitoring is not required for most patients using topical Protopic because systemic exposure is minimal. Nonetheless, dermatologists may recommend:
Patients should schedule follow-up visits every 2-4 weeks during the initial treatment phase and as directed thereafter.
This article provides educational information about Protopic and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
For facial eczema or sensitive areas, start with the 0.03 % ointment once daily. If tolerated and additional control is needed, increase to twice daily under dermatologist supervision.
Avoid applying the ointment to open wounds, severe cuts, or areas with active infection. Apply only to intact, cleaned skin to minimize irritation and infection risk.
Both strengths are supplied in a white, opaque tube with a flip-top cap. The 0.03 % version is labeled “Tacrolimus 0.03 %” and the 0.1 % version reads “Tacrolimus 0.1 %”. Checking the label on the tube’s side ensures correct strength selection.
Topical tacrolimus does not typically produce detectable levels in urine or blood used for standard employment drug screens. However, if a specific immunosuppressant test is ordered, disclose use to the testing authority.
Yes. Keep the tube in its original packaging, place it in a clear, resealable bag, and ensure it complies with liquid limits (generally ≤100 ml). The ointment is non-controlled and poses no security issue.
Moisturizers can be applied after the ointment has absorbed (usually 10-15 minutes). Short courses of low-potency corticosteroids may be used intermittently under medical advice, but long-term steroid-tacrolimus combos are discouraged due to cumulative skin thinning risk.
Unopened tubes retain full potency for up to 24 months from the manufacturing date, provided they are stored as directed. The expiration date is printed on the tube’s label.
Clinical studies show the 0.1 % concentration provides greater anti-inflammatory effect for more extensive or resistant lesions, while the 0.03 % strength is effective for milder disease and sensitive areas. Choice of strength should be individualized.
Protopic offers a steroid-sparing alternative, eliminating risks such as skin atrophy and telangiectasia associated with prolonged steroid use. It may be preferred for facial or intertriginous regions where steroids are less suitable. However, onset of action can be slower, and cost may be higher.
Protopic’s inactive ingredients include polyethylene glycol, polysorbate 80, and methylparaben. Individuals with known sensitivities to these substances should discuss alternatives with their dermatologist.
